Do analysts rate NXL or NSPR?

InspireMD has a consensus price target of $4.50, indicating a potential upside of 539.30%. Given InspireMD's stronger consensus rating and higher probable upside, analysts plainly believe InspireMD is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 InspireMD 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media favor NXL or NSPR?

In the previous week, Nexalin Technology and Nexalin Technology both had 1 articles in the media. Nexalin Technology's average media sentiment score of 0.00 equaled InspireMD'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nexalin Technology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InspireMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate NXL or PETV?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is NXL or PETV more profitable?

PetVivo has a net margin of -902.82% compared to Nexalin Technology's net margin of -3,018.12%. Nexalin Technology's return on equity of -191.88% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets Nexalin Technology -3,018.12% -191.88% -166.43% PetVivo -902.82% -4,813.07% -281.78%

Does the media favor NXL or PETV?

In the previous week, PetVivo had 2 more articles in the media than Nexalin Technology. MarketBeat recorded 3 mentions for PetVivo and 1 mentions for Nexalin Technology. Nexalin Technology's average media sentiment score of 0.00 equaled PetVivo'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nexalin Technology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PetVivo 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PSTV or NXL?

Plus Therapeutics currently has a consensus price target of $56.40, suggesting a potential upside of 1,372.58%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Plus Therapeutics is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to PSTV or NXL?

In the previous week, Plus Therapeutics had 1 more articles in the media than Nexalin Technology. MarketBeat recorded 2 mentions for Plus Therapeutics and 1 mentions for Nexalin Technology. Plus Therapeutics' average media sentiment score of 0.00 equaled Nexalin Technology'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nexalin Technology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CTSO or NXL?

Cytosorbents presently has a consensus target price of $5.38, suggesting a potential upside of 1,314.10%. Given Cytosorbents' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cytosorbents is more favorable than Nexalin Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor CTSO or NXL?

In the previous week, Cytosorbents and Cytosorbents both had 1 articles in the media. Cytosorbents' average media sentiment score of 0.00 equaled Nexalin Technology'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nexalin Technology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend POAI or NXL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Nexalin Technology (NXL) Competitors

$0.49 +0.01 (+2.89%)

Closing price 04:00 PM Eastern

Extended Trading

$0.50 +0.01 (+1.77%)

As of 06:19 PM Eastern

Compare

NXL vs. NSPR, PETV, PSTV, CTSO, and POAI

Should you buy Nexalin Technology stock or one of its competitors? MarketBeat compares Nexalin Technology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nexalin Technology include InspireMD (NSPR), PetVivo (PETV), Plus Therapeutics (PSTV), Cytosorbents (CTSO), and Predictive Oncology (POAI). These companies are all part of the "medical equipment" industry.

How does Nexalin Technology compare to InspireMD?

Nexalin Technology (NASDAQ:NXL) and InspireMD (NYSE:NSPR) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

InspireMD has a net margin of -413.96% compared to Nexalin Technology's net margin of -3,018.12%. InspireMD's return on equity of -69.42% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
InspireMD	-413.96%	-69.42%	-57.68%

0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 16.9% of Nexalin Technology shares are owned by company insiders. Comparatively, 34.1% of InspireMD shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Nexalin Technology has a beta of 4, meaning that its stock price is 300% more volatile than the broader market. Comparatively, InspireMD has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Nexalin Technology has higher earnings, but lower revenue than InspireMD. Nexalin Technology is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	36.05	-$8.22M	-$0.47	N/A
InspireMD	$10.85M	3.04	-$19.92M	-$0.73	N/A

InspireMD has a consensus price target of $4.50, indicating a potential upside of 539.30%. Given InspireMD's stronger consensus rating and higher probable upside, analysts plainly believe InspireMD is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Nexalin Technology and Nexalin Technology both had 1 articles in the media. Nexalin Technology's average media sentiment score of 0.00 equaled InspireMD'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nexalin Technology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InspireMD	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

InspireMD beats Nexalin Technology on 10 of the 14 factors compared between the two stocks.

How does Nexalin Technology compare to PetVivo?

Nexalin Technology (NASDAQ:NXL) and PetVivo (NASDAQ:PETV) are both small-cap medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

PetVivo has a net margin of -902.82% compared to Nexalin Technology's net margin of -3,018.12%. Nexalin Technology's return on equity of -191.88% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
PetVivo	-902.82%	-4,813.07%	-281.78%

0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 24.5% of PetVivo shares are owned by institutional investors. 16.9% of Nexalin Technology shares are owned by insiders. Comparatively, 10.8% of PetVivo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Nexalin Technology has a beta of 4, meaning that its share price is 300% more volatile than the broader market. Comparatively, PetVivo has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Nexalin Technology has higher earnings, but lower revenue than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	36.05	-$8.22M	-$0.47	N/A
PetVivo	$1.05M	27.67	-$10.95M	-$0.38	N/A

In the previous week, PetVivo had 2 more articles in the media than Nexalin Technology. MarketBeat recorded 3 mentions for PetVivo and 1 mentions for Nexalin Technology. Nexalin Technology's average media sentiment score of 0.00 equaled PetVivo'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nexalin Technology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PetVivo	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Nexalin Technology beats PetVivo on 8 of the 13 factors compared between the two stocks.

How does Nexalin Technology compare to Plus Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Nexalin Technology has lower revenue, but higher earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$5.21M	5.06	-$22.39M	-$2.30	N/A
Nexalin Technology	$300K	36.05	-$8.22M	-$0.47	N/A

3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are owned by institutional investors. 2.5% of Plus Therapeutics shares are owned by company insiders. Comparatively, 16.9% of Nexalin Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Plus Therapeutics currently has a consensus price target of $56.40, suggesting a potential upside of 1,372.58%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Plus Therapeutics is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Plus Therapeutics had 1 more articles in the media than Nexalin Technology. MarketBeat recorded 2 mentions for Plus Therapeutics and 1 mentions for Nexalin Technology. Plus Therapeutics' average media sentiment score of 0.00 equaled Nexalin Technology'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nexalin Technology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Plus Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Nexalin Technology has a beta of 4, meaning that its share price is 300% more volatile than the broader market.

Plus Therapeutics has a net margin of -230.24% compared to Nexalin Technology's net margin of -3,018.12%. Nexalin Technology's return on equity of -191.88% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Nexalin Technology	-3,018.12%	-191.88%	-166.43%

Summary

Plus Therapeutics beats Nexalin Technology on 8 of the 15 factors compared between the two stocks.

How does Nexalin Technology compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

In the previous week, Cytosorbents and Cytosorbents both had 1 articles in the media. Cytosorbents' average media sentiment score of 0.00 equaled Nexalin Technology'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nexalin Technology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are held by institutional investors. 7.8% of Cytosorbents shares are held by insiders. Comparatively, 16.9% of Nexalin Technology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cytosorbents has a net margin of -31.85% compared to Nexalin Technology's net margin of -3,018.12%. Nexalin Technology's return on equity of -191.88% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Nexalin Technology	-3,018.12%	-191.88%	-166.43%

Cytosorbents presently has a consensus target price of $5.38, suggesting a potential upside of 1,314.10%. Given Cytosorbents' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cytosorbents is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cytosorbents has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Nexalin Technology has a beta of 4, indicating that its stock price is 300% more volatile than the broader market.

Cytosorbents has higher revenue and earnings than Nexalin Technology. Cytosorbents is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.64	-$8.20M	-$0.19	N/A
Nexalin Technology	$300K	36.05	-$8.22M	-$0.47	N/A

Summary

Cytosorbents beats Nexalin Technology on 9 of the 14 factors compared between the two stocks.

How does Nexalin Technology compare to Predictive Oncology?

Predictive Oncology (NASDAQ:POAI) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

In the previous week, Nexalin Technology had 1 more articles in the media than Predictive Oncology. MarketBeat recorded 1 mentions for Nexalin Technology and 0 mentions for Predictive Oncology. Predictive Oncology's average media sentiment score of 0.00 equaled Nexalin Technology'saverage media sentiment score.

Company	Overall Sentiment
Predictive Oncology	Neutral
Nexalin Technology	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nexalin Technology has a net margin of -3,018.12% compared to Predictive Oncology's net margin of -5,065.23%. Nexalin Technology's return on equity of -191.88% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
Nexalin Technology	-3,018.12%	-191.88%	-166.43%

Nexalin Technology has lower revenue, but higher earnings than Predictive Oncology. Nexalin Technology is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	14.01	-$12.66M	-$13.50	N/A
Nexalin Technology	$300K	36.05	-$8.22M	-$0.47	N/A

9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by insiders. Comparatively, 16.9% of Nexalin Technology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Predictive Oncology has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Nexalin Technology has a beta of 4, indicating that its stock price is 300% more volatile than the broader market.

Summary

Nexalin Technology beats Predictive Oncology on 9 of the 12 factors compared between the two stocks.

Get Nexalin Technology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NXL vs. The Competition

Export

Metric	Nexalin Technology	Technology Services Industry	Business Sector	NASDAQ Exchange
Market Cap	$10.51M	$3.50B	$6.77B	$12.28B
Dividend Yield	N/A	2.23%	3.06%	9.39%
P/E Ratio	-1.05	33.35	28.35	23.94
Price / Sales	36.05	42.25	341.19	91.95
Price / Cash	N/A	34.44	22.57	47.25
Price / Book	2.46	3.95	5.66	6.14
Net Income	-$8.22M	$31.76M	$203.13M	$331.74M
7 Day Performance	23.60%	-4.50%	-2.06%	-1.72%
1 Month Performance	33.51%	0.69%	1.09%	-1.44%
1 Year Performance	-54.93%	-3.79%	8.77%	16.97%

Nexalin Technology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NXL Nexalin Technology	0.1283 of 5 stars	$0.49 +2.9%	N/A	-56.2%	$10.51M	$300K	N/A	3	Gap Up
NSPR InspireMD	3.3476 of 5 stars	$0.72 -0.2%	$4.50 +527.2%	-70.6%	$33.61M	$10.85M	N/A	50	Gap Up
PETV PetVivo	N/A	$0.77 +1.1%	N/A	-3.9%	$28.89M	$1.05M	N/A	20	Gap Down
PSTV Plus Therapeutics	2.2358 of 5 stars	$4.28 +2.6%	$56.40 +1,217.8%	-59.7%	$28.71M	$5.21M	N/A	20
CTSO Cytosorbents	2.5685 of 5 stars	$0.39 +2.2%	$5.38 +1,283.5%	-65.0%	$23.88M	$37.06M	N/A	220	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NXL) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nexalin Technology (NXL) Competitors

NXL vs. NSPR, PETV, PSTV, CTSO, and POAI

How does Nexalin Technology compare to InspireMD?

Summary

How does Nexalin Technology compare to PetVivo?

Summary

How does Nexalin Technology compare to Plus Therapeutics?

Summary

How does Nexalin Technology compare to Cytosorbents?

Summary

How does Nexalin Technology compare to Predictive Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXL vs. The Competition

Nexalin Technology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nexalin Technology (NXL) Competitors

NXL vs. NSPR, PETV, PSTV, CTSO, and POAI

How does Nexalin Technology compare to InspireMD?

Is NXL or NSPR more profitable?

Do insiders and institutionals believe in NXL or NSPR?

Which has more risk and volatility, NXL or NSPR?

Which has preferable earnings and valuation, NXL or NSPR?

Do analysts rate NXL or NSPR?

Does the media favor NXL or NSPR?

Summary

How does Nexalin Technology compare to PetVivo?

Is NXL or PETV more profitable?

Do institutionals & insiders believe in NXL or PETV?

Which has more risk & volatility, NXL or PETV?

Do analysts rate NXL or PETV?

Which has better valuation and earnings, NXL or PETV?

Does the media favor NXL or PETV?

Summary

How does Nexalin Technology compare to Plus Therapeutics?

Which has higher earnings and valuation, PSTV or NXL?

Do insiders and institutionals hold more shares of PSTV or NXL?

Do analysts recommend PSTV or NXL?

Does the media refer more to PSTV or NXL?

Which has more risk and volatility, PSTV or NXL?

Is PSTV or NXL more profitable?

Summary

How does Nexalin Technology compare to Cytosorbents?

Does the media favor CTSO or NXL?

Do insiders & institutionals have more ownership in CTSO or NXL?

Is CTSO or NXL more profitable?

Do analysts prefer CTSO or NXL?

Which has more volatility & risk, CTSO or NXL?

Which has higher valuation & earnings, CTSO or NXL?

Summary

How does Nexalin Technology compare to Predictive Oncology?

Does the media refer more to POAI or NXL?

Do analysts recommend POAI or NXL?

Is POAI or NXL more profitable?

Which has stronger earnings & valuation, POAI or NXL?

Do institutionals and insiders hold more shares of POAI or NXL?

Which has more volatility & risk, POAI or NXL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXL vs. The Competition

Nexalin Technology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools